Inari Medical
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 1.3K
- Market Cap
- -
- Introduction
Inari Medical, Inc. operates as a medical device company. The firm develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. Its products include FlowTriever system and ClotTriever system. The company was founded by Brian J. Cox, Paul Lubock and Robert F. Rosenbluth in June 2011 and is headquartered in Irvine, CA.
Stryker Unveils Artix Thrombectomy System: A Breakthrough in Arterial Blood Clot Treatment
Stryker's newly launched Artix Thrombectomy System combines mechanical thrombectomy and aspiration capabilities, offering a novel solution for treating arterial blood clots in peripheral vessels.
Endovascular Advancements: New Devices and Strategies Emerge for PAD and CLTI
Large-bore mechanical thrombectomy demonstrates superiority over catheter-directed thrombolysis in acute intermediate-risk pulmonary embolism, reducing clinical deterioration and ICU stays.
VIVA24: Late-Breaking Trials Highlight Advances in Vascular Intervention
The PROMISE II trial demonstrates sustained limb salvage and wound healing at 2 years using the LimFlow System for no-option CLTI patients.
VIVA24: Late-Breaking Trials Highlight Advances in Peripheral Artery Disease Treatment
The PROMISE II trial demonstrates sustained limb salvage and wound healing at two years using the LimFlow System for no-option CLTI patients.
VIVA24: Novel Therapies Show Promise in Vascular Disease Treatment
The Esprit BTK scaffold demonstrated superior long-term outcomes in treating chronic limb-threatening ischemia compared to percutaneous transluminal angioplasty.
VIVA24: Novel Therapies Show Promise in Vascular Disease Treatment
The Esprit BTK scaffold demonstrated superior long-term outcomes compared to PTA in treating chronic limb-threatening ischemia, with a 61.5% limb salvage and primary patency rate at 2 years.
TCT Conference Highlights: Edwards, Medtronic, and Inari Share Key Trial Data
Edwards Lifesciences' tricuspid valve replacement device met its primary endpoint in a trial, showing improvement in patient-reported quality of life but no significant mortality benefit at 12 months.
Inari Medical's FlowTriever Demonstrates Superiority Over Thrombolytics in Pulmonary Embolism Trial
The PEERLESS trial demonstrated that Inari Medical's FlowTriever system significantly reduced clinical deterioration and therapy escalation compared to catheter-directed thrombolytics (CDT) in intermediate-risk pulmonary embolism (PE) patients.
FDA Updates: Approvals for RSV Vaccine, Pneumococcal Vaccine, and TB Drug Alongside Device Recalls
The FDA granted traditional approval to Sirturo (bedaquiline) for treating rifampin- and isoniazid-resistant tuberculosis in adults and children, based on Phase 3 STREAM study data.
Inari Medical's PEERLESS Trial Data to be Unveiled at TCT 2024
Inari Medical's PEERLESS trial data, comparing FlowTriever with catheter-directed thrombolysis for intermediate-risk pulmonary embolism, will be presented at TCT 2024.